Zenith Capital Corp.

Equities

ZHCLF

CA98935N1033

Delayed OTC Markets Other stock markets 10:16:38 28/05/2024 pm IST			5-day change	1st Jan Change
0.13 ^USD	+30.00%		+30.00%	+8.33%

05/04	Zenith Capital Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2024	CI
2023	Zenith Capital Corp. Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2023	CI

Zenith Epigenetics Announces Resignation of Arthur Higgins from Board

February 11, 2014 at 10:30 pm IST

Zenith Epigenetics announced that Arthur Higgins will be stepping down from the board of directors after fulfilling his commitment in helping Zenith Epigenetics to be established as a spin out company from Resverlogix Corp.

Latest news about Zenith Capital Corp.

Zenith Capital Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2024	06/04	CI
Zenith Capital Corp. Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2023	23/12	CI
Zenith Capital Corp. Reports Earnings Results for the First Quarter Ended July 31, 2023	28/23/28	CI
Zenith Capital Corp. Reports Earnings Results for the Full Year Ended April 30, 2023	29/23/29	CI
Zenith's Bet Inhibitor ZEN-3694 Providing Significant Clinical Benefit in Patients with Aggressive Cancer Type	01/23/01	CI
Zenith Capital Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2023	07/23/07	CI
Zenith Capital Corp. Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2022	24/22/24	CI
Zenith Capital Corp. Reports Earnings Results for the First Quarter Ended July 31, 2022	30/22/30	CI
Zenith Capital Corp. Auditor Raises 'Going Concern' Doubt	15/22/15	CI
Zenith Capital Corp. Reports Earnings Results for the Full Year Ended April 30, 2022	15/22/15	CI
Zenith Epigenetics Announces Initiation of Phase 2b Triple Negative Breast Cancer Clinical Trial	10/22/10	CI
Zenith Capital Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2022	01/22/01	CI
Zenith Epigenetics Provides Clinical Update	31/22/31	CI
Zenith Epigenetics Announces Changes to Board of Directors	31/22/31	CI
Zenith Capital Corp. Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2021	20/21/20	CI
Newsoara BioPharma Co., Ltd. announced that it expects to receive $1.5 million in funding from Zenith Capital Corp.	15/21/15	CI
Zenith Capital Corp. Reports Earnings Results for the Full Year Ended April 30, 2021	31/21/31	CI
Zenith Capital Corp. Auditor Raises 'Going Concern' Doubt	30/21/30	CI
Zenith Epigenetics Announces a Publication Highlighting the Role of ZEN-3694 in Overcoming Resistance to Therapies in Metastatic Castration-Resistant Prostate Cancer	24/21/24	CI
Zenith Epigenetics Announces Clinical Collaboration with Astellas	22/21/22	CI
Zenith Capital Corp. Reports Earnings Results for the Third Quarter Ended January 31, 2021	07/21/07	CI
Zenith Epigenetics Announces Dosing of First Mcrpc Patient with A Combination of Zen-3694 + Merck's Immune Check Point Inhibitor Keytruda	15/21/15	CI
Zenith Capital Corp. Auditor Raises 'Going Concern' Doubt	09/20/09	CI
Zenith Epigenetics Announces Collaboration with Nci in Developing Zen-3694 for Multiple Oncology Indications	05/20/05	CI
Zenith Capital Corp. announced that it has received $5.000001 million in funding from Newsoara BioPharma Co., Ltd.	08/20/08	CI

Chart Zenith Capital Corp.

Duration

Period

More charts

Company Profile

Sector

Calendar

27/08/2024 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data